Pharmafile Logo

Fit-for-purpose matchmaking webinar: a data selection and RWE approach for both regulatory and HTA audiences

This webinar reviews considerations for the design and data selection for RWE studies, including external control arm studies, to meet regulatory and HTA needs.

Regulators and agencies responsible for market authorization and health technology assessment (HTA) are increasingly using real-world evidence (RWE) to enhance their decision-making. Life sciences companies must ensure that data utilized for RWE generation is considered fit-for-purpose.

Focusing on an external control arm (ECA) use case, we will share lessons learned highlighting the advantages of a data-agnostic approach to data selection, understanding regulatory and HTA expectations, and obtaining diverse stakeholder insights. The audience will gain appreciation for considering multiple perspectives, including regulators, HTAs and payers, when evaluating data and planning for RWE submissions.

Of interest to all those interested in: pharmacoepidemiology, RWE, market access, manufacturers, biotech, data vendors.

This content was provided by Genesis Research Group

Company Details

 Latest Content from  Genesis Research Group 

Genesis Research Acquires Market Access Transformation

Genesis Research, a leading provider of tech-enabled Real-World Evidence (RWE) and Health Economics and Outcomes Research (HEOR) services, has entered into a definitive agreement to acquire Market Access Transformation (“MAT”),...

GHO Capital Acquires Genesis Research

GHO Capital Partners LLP, the European specialist investor in global healthcare, announces the acquisition of Genesis Research, a leading provider of tech-enabled Real-World Evidence (RWE) and Health Economics and Outcomes...

Genesis Research: What is EVID AI?

Genesis Research Announces Significant Enhancements to EVID AI, the World's Largest AI-Enabled Healthcare Literature Database for Faster, More Efficient Searches